Literature DB >> 10494765

Inconsistency of association between type 1 von Willebrand disease phenotype and genotype in families identified in an epidemiological investigation.

G Castaman1, J C Eikenboom, R M Bertina, F Rodeghiero.   

Abstract

In a previous epidemiological investigation among schoolchildren of Northern Italy, a conservative 1% prevalence of type 1 von Willebrand disease (VWD) was found. Diagnosis was based on a positive family history and low von Willebrand factor (VWF) ristocetin cofactor activity. To investigate whether the type 1 VWD phenotype as detected by our original methodology cosegregates with one or more specific alleles of the VWF gene, we have performed genotype analysis in affected subjects and their family members. Eleven of the 14 subjects previously identified as having VWD, all with mild personal bleeding symptoms, agreed to participate in the genetic study. Remarkably, the laboratory measurements of the previous investigation were completely confirmed in 10 of the 11 subjects. Clear cosegregation of the VWD type 1 and a specific VWF allele was observed in one family and was likely in the family of two other pro-bands. In three additional propositi and their families a possible association of the phenotype with a VWF allele was found. No association was observed in the remaining five subjects and their families. During 13-year follow-up few additional bleeding episodes were recorded among investigated subjects, most often occurring in the one family manifesting clear cosegregation. The results of this study illustrate that a personal and family bleeding history and persistently low VWF ristocetin cofactor activity, fitting the usual criteria for type 1 VWD, may not cosegregate with genetic markers at the VWF gene locus. Thus the prevalence of VWD defined as a disorder involving the VWF locus might be overestimated in population study. However, phenotypic diagnosis still remains fundamental to identify patients at risk of bleeding. Further research should clarify whether in families with more severe clinical and laboratory phenotype a clear association with markers of VWF is found.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10494765

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  14 in total

1.  Rapid discrimination of the phenotypic variants of von Willebrand disease.

Authors:  Jonathan C Roberts; Patti A Morateck; Pamela A Christopherson; Ke Yan; Raymond G Hoffmann; Joan Cox Gill; Robert R Montgomery
Journal:  Blood       Date:  2016-02-25       Impact factor: 22.113

2.  Heavy menstrual bleeding and health-associated quality of life in women with von Willebrand's disease.

Authors:  Igor Govorov; Lena Ekelund; Roza Chaireti; Petra Elfvinge; Margareta Holmström; Katarina Bremme; Miriam Mints
Journal:  Exp Ther Med       Date:  2016-03-10       Impact factor: 2.447

3.  Assay of the von Willebrand factor (VWF) propeptide to identify patients with type 1 von Willebrand disease with decreased VWF survival.

Authors:  Sandra L Haberichter; Michael Balistreri; Pamela Christopherson; Patricia Morateck; Stefana Gavazova; Daniel B Bellissimo; Marilyn J Manco-Johnson; Joan Cox Gill; Robert R Montgomery
Journal:  Blood       Date:  2006-07-11       Impact factor: 22.113

4.  The utility of the DDAVP challenge test in children with low von Willebrand factor.

Authors:  Natasha M Archer; Mihail Samnaliev; Rachael Grace; Carlo Brugnara
Journal:  Br J Haematol       Date:  2015-03-02       Impact factor: 6.998

5.  Genetic regulation of plasma von Willebrand factor levels: quantitative trait loci analysis in a mouse model.

Authors:  H L Lemmerhirt; K W Broman; J A Shavit; D Ginsburg
Journal:  J Thromb Haemost       Date:  2006-11-28       Impact factor: 5.824

Review 6.  Women and bleeding disorders: diagnostic challenges.

Authors:  Paula D James
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2020-12-04

7.  An apparently silent nucleotide substitution (c.7056C>T) in the von Willebrand factor gene is responsible for type 1 von Willebrand disease.

Authors:  Viviana Daidone; Lisa Gallinaro; Maria Grazia Cattini; Elena Pontara; Antonella Bertomoro; Antonio Pagnan; Alessandra Casonato
Journal:  Haematologica       Date:  2011-03-10       Impact factor: 9.941

8.  Identification of type 1 von Willebrand disease patients with reduced von Willebrand factor survival by assay of the VWF propeptide in the European study: molecular and clinical markers for the diagnosis and management of type 1 VWD (MCMDM-1VWD).

Authors:  Sandra L Haberichter; Giancarlo Castaman; Ulrich Budde; Ian Peake; Anne Goodeve; Francesco Rodeghiero; Augusto B Federici; Javier Batlle; Dominique Meyer; Claudine Mazurier; Jenny Goudemand; Jeroen Eikenboom; Reinhard Schneppenheim; Jorgen Ingerslev; Zdena Vorlova; David Habart; Lars Holmberg; Stefan Lethagen; John Pasi; Frank G H Hill; Robert R Montgomery
Journal:  Blood       Date:  2008-03-14       Impact factor: 22.113

Review 9.  Principles of care for the diagnosis and treatment of von Willebrand disease.

Authors:  Giancarlo Castaman; Anne Goodeve; Jeroen Eikenboom
Journal:  Haematologica       Date:  2013-05       Impact factor: 9.941

10.  ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease.

Authors:  Paula D James; Nathan T Connell; Barbara Ameer; Jorge Di Paola; Jeroen Eikenboom; Nicolas Giraud; Sandra Haberichter; Vicki Jacobs-Pratt; Barbara Konkle; Claire McLintock; Simon McRae; Robert R Montgomery; James S O'Donnell; Nikole Scappe; Robert Sidonio; Veronica H Flood; Nedaa Husainat; Mohamad A Kalot; Reem A Mustafa
Journal:  Blood Adv       Date:  2021-01-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.